^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
Published date:
07/05/2021
Excerpt:
A total of 206 patients were assessed, including 92 cutaneous melanoma patients with 12 NRAS mutations and 114 noncutaneous melanoma patients with 21 NRAS mutations….NRAS wild-type melanoma included patients with BRAF or KIT mutations….In cutaneous melanoma, 21 from 92 patients had NRAS mutations. The overall ORR of anti-PD-1 monotherapy in the NRAS mutant population was 9.5%, which was lower than the rate of 23.9% among the wild-type patients (P=0.223).
DOI:
10.3389/fimmu.2021.691032
Trial ID:
